Christopher T. Ritchlin

Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double‐blind, randomized, placebo‐controlled trial

Philip J. Mease, Dafna D. Gladman, Christopher T. Ritchlin et al. · Arthritis & Rheumatism · 2005 · 905 citations

Medicine, Pharmacology, Pharmacotherapy +15

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis

Laura C. Coates, Arthur Kavanaugh, Philip J. Mease et al. · Arthritis & Rheumatology · 2016 · 904 citations · Full text

Medicine, Clinical Sciences, Dermatology +13

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

Iain B. McInnes, Arthur Kavanaugh, Alice B. Gottlieb et al. · The Lancet · 2013 · 798 citations

Medicine, Clinical Sciences, Immunology +10

Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force

Josef S Smolen, Monika Schöls, Jürgen Braun et al. · Annals of the Rheumatic Diseases · 2017 · 676 citations · Full text

Medicine, Dermatology, Internal Medicine +14

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial

Christopher T. Ritchlin, Proton Rahman, Arthur Kavanaugh et al. · Annals of the Rheumatic Diseases · 2014 · 658 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14